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Abstract
Background: Diabetes is a risk factor for cardiovascular diseases (CVDs) and there are reports of increasing
prevalence of prediabetes in Nigeria. This study therefore characterised CVDs risk factors in subjects with impaired
fasting glucose (IFG) and diabetes.
Methods: Data from 4 population-based cross-sectional studies on 2447 apparently healthy individuals from
18 - 89 years were analysed. Anthropometric, blood pressure and biochemical parameters were collected and
classified. Individuals with IFG (prediabetes) and diabetes were merged each for positive cases of
dyslipidaemia, high blood pressure (HBP) or obesity. Optimal Discriminant and Hierarchical Optimal
Classification Tree Analysis (HO-CTA) were employed.
Results: Overall prevalence of IFG and diabetes were 5.8% (CI: 4.9 – 6.7%) and 3.1% (CI: 2.4 – 3.8%),
respectively. IFG co-morbidity with dyslipidaemia (5.0%; CI: 4.1 – 5.8%) was the highest followed by
overweight/obese (3.1%; CI: 2.5 – 3.8%) and HBP (1.8%; CI: 1.3 – 2.4%). The predicted age of IFG or diabetes
and their co-morbidity with other CVD risk factors were between 40 – 45 years. Elevated blood level of total
cholesterol was the most predictive co-morbid risk factor among IFG and diabetes subjects.
Hypertriglyceridaemia was an important risk factor among IFG-normocholesterolaemic-overweight/obese
individuals.
Conclusion: The higher prevalence of co-morbidity of CVD risk factors with IFG than in diabetes plus the
similar age of co-morbidity between IFG and diabetes highlights the need for risk assessment models for
prediabetes and education of individuals at risk about factors that mitigate development of diabetes and
CVDs.
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Background
Impaired fasting glucose (IFG) is a hyperglycaemic condi-
tion that predisposes individuals to high risk of developing
type II diabetes (T2D) and cardiovascular disease (CVD)
[1]. It is characterised by insulin resistance, beta cell dys-
function, increased lipolysis, inflammation, sub-optimal
incretin effect and hepatic glucose overproduction [2].
There have been debates on whether IFG, a compo-
nent of prediabetes, should be considered in the same
manner with T2D since in both conditions there is
hyperglycaemic-induced toxicity [3, 4]. It is noted that
progression from IFG to T2D can occur due to wors-
ening oxidative stress [3], insulin resistance or beta
cell dysfunction [4], and in the long term predisposes
to increased risk of CVD. This is where routine
screening can be beneficial in aiding early identifica-
tion and application of management practices, since
the process of progression is not abrupt.
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In Africa, more than two thirds of people with diabetes
are undiagnosed [5], giving room for complete transition
of the early stages of impaired glucose regulation to
overt disease condition. About 14.2 and 34.9 million
adults of age 20 – 79 years have diabetes and prediabetes
with estimated prevalence of 3.2% (2.1 – 6.7%) and 7.9%
(4.8 – 21.9%), respectively. However, the most glaring
part is the indication that the prevalence of prediabetes
will double by the year 2040 and this is more than that
projected for T2D [5]. Based on the 2013 Global Burden
of Disease study [6], about 90.5% of stroke burden was
attributable to lifestyle-related risk factors, cluster of
metabolic risk factors (high blood pressure, IFG, elevated
total cholesterol and low glomerular infiltration) and en-
vironmental factors. Lifestyle-related risk factors and
metabolic risk factors contributed to 74.2% and 72.4%
stoke burden, respectively and the population attribut-
able fraction of risk factors in low-middle-income coun-
tries increased from 1990 to 2013 [6]. Such observations
therefore call for periodic screening, monitoring and ap-
praisal of data on risk factors for metabolic diseases.
CVD risk screening in Nigeria is sub-optimal, even
though evidence indicates early onset of disease burden
[7, 8], which in part contributes to the low life expect-
ancy and quality of life of Nigerians [9]. One of the
effective approaches to early identification of CVD risk
is the utilisation of risk assessment models and these
have been shown to be better than clinical judgement
[10]. Although the assessment of co-occurrence of risk
factors for CVD is largely studied in diabetic patients
[11–14], the extent that these trends affect the seemingly
healthy populations with IFG in Nigeria needs to be
documented.
The use of risk assessment models, which provide the
bedrock for early identification of diabetes and conse-
quential CVD within a resource constraint population
are unclear within African population [15]. Therefore,
this study seeks to characterise CVD risk factors in sub-
jects with impaired fasting glucose (IFG) and diabetes by
specifically predicting the age of IFG and diabetes co-
morbidity with CVD risk factors and to classify the risk
factors in IFG in a large apparently healthy Nigerian
population.
Methods
Study population, setting and ethics clearance
This was a consolidation of data from 4 population-
based cross-sectional studies on apparently healthy indi-
viduals from 18 to 89 years in 4 geopolitical zones of
Nigeria as reported [16]. Participants were drawn from a
representative sample populations in Ndokwa West
Local Government Area (LGA) of Delta State and indi-
genes of Ndokwa residing in Lagos State; Enugu North
LGA and Enugu Municipality of Enugu State; and FCT
Abuja. Participants gave informed consent and were
recruited if they confirmed that they had no case or
history of chronic kidney disease and diabetes and, were
not pregnant or under treatment for high blood
pressure.
In each of the study location, participants were drawn
from both rural and urban settings. The main occupa-
tion of participants from rural populations is farming,
while those in the urban setting are majorly employed as
artisans, traders and in white-collar jobs. Yearly average
temperature of study areas is 24oC (19 - 33oC). Partici-
pants were mobilised to attend designated study sites lo-
cated at churches, town halls, school premises and
primary health centres. Sample size was calculated based
on two estimates since several CVD risk factors with dif-
ferent prevalence were involved. Firstly, estimated 5%
prevalence of diabetes [17] at 5% confidence interval and
at 95% confidence level gave a minimum sample size of
73. In regards to other CVD risk factors, minimum esti-
mate of 384 sample size was also required given a pro-
jected 50% prevalence of hypertension and dyslipidaemia
[18, 19] at 5% confidence interval and at 95% confidence
level. However, the total sample size of 2447 in this
study was above the minimum estimates for the various
CVD risk factors assessed. The Human Research Ethics
Committee of Charles Darwin University, Australia
(HREC Ref: H14003); HREC of Novena University
Nigeria. Ethics Review Committee (ERC) of the Univer-
sity of Nigeria Teaching Hospital, and ERC of Enugu
State Ministry of Health. ERC of Benue State University
Nigeria; Abuja Municipal and Kuje Area Councils
Ethical Committees, approved the study.
Anthropometric and blood pressure measurements
The standard techniques and procedures for measure-
ment of waist circumference, weight and height were as
reported [20–24]. The body mass index (BMI) was
calculated by dividing the weight with height square
(Kg/m2). BMI values were grouped into underweight
(<18.5 Kg/m2), normal weight (18.5 – 24.9 Kg/m2), over-
weight (25.0 – 29.9 Kg/m2) and obese (>30 Kg/m2).
Three readings of the systolic (SBP) and diastolic blood
pressures (DBP) were taken using Omron® (Australia)
digital and Accoson® mercury sphygmomanometer then
the average of 2nd and 3rd readings was used to ascertain
the blood pressure for all the study sites.
Biochemical parameters
Participants fasted for at least 8 h before blood samples
were collected for fasting blood glucose (FBG) and lipids
analyses. Blood sample collections were carried out in
different locations, such as town halls, health centres
and churches, based on convenience of participants.
EasyLog EL-USB-1® (Lascar Electronics, Australia)
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temperature data logger was used to monitor and ensure
optimal operational temperature and humidity for point
of care blood analysis. The temperature data logger was
set 19.5oC low alarm and 30.5oC high alarm. For analysis
using clinical laboratory techniques, blood sample were
collected in fluoride oxalate bottles. Based on manufac-
turers’ guideline, the following screening techniques were
used based on study location as earlier described [16].
Fasting blood glucose: CardioChek® Professional Point
of Care Diagnostic Analyser (Polymer Technology Sys-
tems, Inc, IN, USA) [site 1] and Accuchek® Point of Care
Diagnostic Analyser (Roche Diagnostics, UK) [site 2]
were employed. At sites 3 and 4, FBG was assessed by
the glucose oxidase method in the reference laboratories
in Abuja and Enugu, Nigeria, respectively.
Lipids profile: Clinical laboratory techniques were used
for screening total cholesterol (TC), triglycerides (TG)
and high density lipoprotein cholesterol (HDL-C) at ref-
erence laboratories in sites 2, 3 and 4. TC and TG were
measured by enzymatic colorimetric method and HDL-
C by differential precipitation followed by enzymatic col-
orimetry using semi-autoanalyser Mitra Photometer
(Linear Chemicals S.L., Barcelona, Spain [site 2], Randox
Laboratories, UK [site 3] and Teco Diagnostics, USA
[site 3]).
The point of care analytical systems (Polymer Technology
Systems and Roche Diagnostics) are certified by the Centre
for Disease Control and Prevention (CDC) to meet clinical
laboratory reference standards [25]. In addition, Cardio-
Chek® Professional Point of Care Diagnostic Analyser has
been shown to demonstrate good clinical agreement with
clinical laboratory reference methods for TC (97%), TG
(92.4%) and HDL-C (92.9%) [26].
Classification of CVD risk factors
The blood glucose level range of 100 – 125 mg/dL (5.6
– 6.9 mmol/L) was used to define impaired fasting glu-
cose (IFG) and values ≥126 mg/dL (7 mmol/L) for dia-
betes when participants fasted for at least 8 h. The cut-
off values employed for the other CVD risk components
are as proposed [27]:
 High blood pressure: Systolic blood pressure
≥140 mmHg and/or diastolic blood pressure
≥90 mmHg [28].
 Hypertriglyceridaemia: Serum triglyceride level of
≥150 mg/dL (1.7 mmol/L) and/or receiving current
medication for the condition [29].
 Low HDL-C: Serum HDL-C level of ≤40 mg/dL
(1 mmol/L) in males and ≤50 mg/dL (1.3 mmol/L)
in females [29].
 Hypercholesterolaemia: Serum total cholesterol level
of ≥200 mg/dL (5.2 mmol/L) and/or receiving
current medication for the condition [29].
Dyslipidaemia was defined when at least one lipid dis-
order (hypertriglyceridaemia, hypercholesterolaemia and
or low HDL-C) was identified.
Statistical analysis
A total of 2809 individuals were pooled from the 4
population-based cross-sectional studies. Study partici-
pants missing values of key study variables such as FBG,
TG, TC, HDL-C, BMI, and SBP/DBP were excluded.
After the exclusion (n = 362), 2447 participants were
used. Descriptive analysis of the study population was
performed showing the mean and standard deviation of
all CVD risk variables across gender. In order to deter-
mine number of participants with IFG/diabetes co-
morbid CVD risk factors, participants with positive tests
for IFG or diabetes were merged with positive cases of
dyslipidaemia, HBP, overweight/obese (based on BMI).
Frequency distribution of IFG and diabetes with their
co-morbid states were calculated and tabulated. Boot-
strapping was applied based on 1000 bootstrap samples
and 95% confidence interval generated.
Optimal Discriminant Analysis (ODA) was carried out
to predict the age at which IFG or diabetes co-morbidity
with CVD risk factors occur across the entire study
population. In this analysis, IFG and diabetes with their
co-morbid risk factors were treated as class variables,
with age of participants as the attribute variable (See
Additional file 1).
Finally, Hierarchical Optimal Classification Tree Ana-
lysis (HO-CTA) using Optimal Discriminant Analysis
(ODA) methods [30] was applied to predict the risk fac-
tors that are associated with IFG as well as to generate a
decision model. HO-CTA has been shown to be better
than linear models that are based on legacy general lin-
ear model and maximum-likelihood paradigms [31]. It is
a nonlinear multivariate classification method and has
an advantage of not requiring any assumptions of multi-
colinearity, multivariate normality, equality of group
sizes, or number of variables [32].
For the HO-CTA, IFG was the dependent (class) vari-
able, while hypercholesterolaemia, hypertriglyceridaemia,
HBP, low serum HDL-C level, age, overweight/obese
(based on BMI), smoking and alcohol status, and popu-
lation (rural vs. urban) were fitted as independent covar-
iates or attribute variables. Leave-one-out re-sampling
was used to identify the most stable predictor (attribute)
variables that maximise generalisability of the HO-CTA
model. The Effect Strength for Sensitivity (ESS) was used
to assess predictor performance in classification of IFG.
ESS is an index of effect strength normed against
chance, where 0 represents classification accuracy ex-
pected by chance and 100 represents errorless classifica-
tion [30]. Analysis was carried out using IBM SPSS
(Version 22 for Windows, IL, USA), UniODA (American
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Psychological Association, USA) and CTA (Optimal
Data Analysis LLC, USA) statistical packages. Level of
significance was set at 0.05.
Results
Baseline characteristics of study population
Table 1 on characteristics of the study population shows
that 2447 participants were selected consisting of 1151
males and 1296 females. The age (p = 0.700) and fasting
blood glucose levels (p = 0.377) of participants were rela-
tively the same across gender.
Prevalence of co-morbid states of IFG and diabetes
The overall prevalence of IFG (5.8%; CI: 4.9 – 6.7%) was
higher than that of diabetes (3.1%; CI: 2.4 – 3.8%). The
highest co-morbid risk factor with IFG was dyslipidae-
mia (5.0%; CI: 4.1 – 5.8%), followed by overweight/obese
(3.1%; CI: 2.5 – 3.8%), then HBP (1.8%; CI: 1.3 – 2.4%).
In diabetes, the prevalence of co-morbid conditions
followed the same trend as in IFG, where co-morbidity
with dyslipidaemia (2.7%; CI: 2.0 – 3.3%) was the highest
and HBP, the lowest prevalent (1.3%; CI: 0.9 – 1.8%)
(Table 2).
Co-morbidity of IFG and diabetes with other CVD risk
factor across age groups
Across the different age groups, the results show that
co-morbidity of IFG and dyslipidaemia was dominant
more than the other risk conditions (Table 3). The low-
est age group, (18 – 29 years) also had a sizeable preva-
lence of IFG and its co-morbid risk factors. The age
group, 40 – 49 years had the highest proportion of indi-
viduals with risk conditions both in IFG and diabetes.
Predicted age of IFG and diabetes co-morbidity with
other CVD risk factors
There was no statistical significant difference between
predicted age of participants with or without IFG, and
IFG co-morbidity with dyslipidaemia and HBP (Table 4).
On the other hand, only diabetes (p = 0.018) and its
co-morbidity with HBP (p = 0.010) showed a statistical
significant difference. In all, predicted age of IFG, dia-
betes and their co-morbid risk conditions were be-
tween 40 – 45 years old.
Classification tree of IFG co-morbid risk factors
Figure 1 shows the order of independent predictive per-
formance of the risk factors in classifying IFG. The high-
est and statistically significant independent predictors of
IFG was elevated blood total cholesterol level (ESS =
17.66%, p < 0.0001), followed by overweight/obese (ESS
= 14.74%, p = 0.001), hypertriglyceridaemia (ESS =
12.82%, p = 0.001) and high blood pressure (ESS = 9.32%,
p = 0.013). However, age (ESS = 8.06%, p = 0.248), low
blood HDL-C level (ESS = 5.89%, p = 0.189), cigarette
smoking (ESS = 4.12%, p = 0.292), alcohol consumption
(ESS = 2.90%, p = 0.609) and population (rural vs. urban)
[ESS = 0.44%, p = 0.930] were not statistically significant.
The classification tree model shown in Fig. 2 also in-
dicates that high level of blood total cholesterol con-
centration is the most prominent/important co-morbid
risk factor among IFG subjects. The result further
shows that among 141 (5.8%) subjects with IFG, 60
(9.5%) have elevated total cholesterol. Among 81








Age (years) 43.4 ± 14.8 43.3 ± 14.6 43.4 ± 15.1 0.700
Weight (Kg) 65.3 ± 18.1 64.6 ± 21.8 66.0 ± 12.5 <0.0001
Height (m) 1.6 ± 0.08 1.6 ± 0.07 1.7 ± 0.08 <0.0001
WC (cm) 84.0 ± 10.9 85.1 ± 11.9 82.9 ± 9.7 <0.0001
BMI (Kg/m2) 24.8 ± 6.2 25.6 ± 7.6 24.1 ± 4.0 <0.0001
WHtR 0.52 ± 0.07 0.54 ± 0.07 0.50 ± 0.06 <0.0001
SBP (mmHg) 122.2 ± 20.4 121.1 ± 21.3 123.5 ± 19.3 <0.0001
DBP (mmHg) 78.1 ± 14.2 77.4 ± 15.6 78.8 ± 12.3 <0.0001
TC (mg/dL) 167.5 ± 52.9 173.5 ± 56.1 160.7 ± 48.1 <0.0001
HDL (mg/dL) 50.9 ± 16.8 52.7 ± 17.5 48.7 ± 15.8 <0.0001
TG (mg/dL) 120.0 ± 49.4 117.1 ± 45.5 123.2 ± 53.3 0.042
FBG (mg/dL) 79.9 ± 30.0 79.7 ± 28.9 80.0 ± 31.3 0.377
WC waist circumference, BMI body mass index, WHtR waist to height ratio, SBP
systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL
high density lipoprotein cholesterol, TG triglycerides, FBG fasting
blood glucose
Table 2 Prevalence of IFG and diabetes co-morbidity with CVD
risk factors








HBP 566 23.1 21.5 24.8 0.8
Hypercholesterolaemia 634 25.9 24.2 27.7 0.9
Hypertriglyceridaemia 572 23.4 21.6 25.1 0.9
Low HDL-C 1073 43.8 41.8 45.7 1.0
Overweight/obese 979 40.0 38.0 42.1 1.0
IFG 141 5.8 4.9 6.7 0.5
IFG + dyslipidaemia 122 5.0 4.2 5.9 0.4
IFG + HBP 64 2.6 2.0 3.3 0.3
IFG + overweight/obese 76 3.1 2.5 3.8 0.4
Diabetes 76 3.1 2.4 3.8 0.4
Diabetes + dyslipidaemia 65 2.7 2.0 3.4 0.3
Diabetes + HBP 47 1.9 1.4 2.5 0.3
Diabetes + overweight/
obese
48 2.0 1.4 2.6 0.3
IFG impaired fasting glucose, + with, HDL high density lipoprotein cholesterol,
HBP high blood pressure, SE standard error
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(4.5%) IFG subjects without high level of total choles-
terol, 39 (6.3%) are overweight/obese. Hypertriglyceri-
daemia is a risk factor in subjects with IFG and are
overweight/obese even if they do not have elevated
blood level of total cholesterol.
Discussion
This study shows that there is higher prevalence of IFG
than undiagnosed diabetes among the study Nigerian
population. Further, co-morbidity of modifiable risk fac-
tors for chronic diabetes and CVD, such as dyslipidae-
mia and HBP, were more predominant in IFG than
diabetes subjects. Several studies report that the
transition to westernised ways of life, which may lead to
unhealthy eating and physical inactivity, is possibly re-
sponsible for this increase in multi-morbidity [33–35]. It
has been shown that the relative risk of coronary heart
disease in individuals with 1, 2 or >3 CVD risk factors is
up to 2, 4 and 7-folds, respectively [14]. More so, the
fact that the hyperglycaemic condition of IFG worsens
the already frail state of endothelial dysfunction and in-
sulin resistance [4], prompts for action on community-
wide implementation of diabetes and CVD risk factor
identification and prevention.
Age distribution of IFG and co-morbidity of IFG with
CVD risk factors showed upward trend from the lowest
age group, plateauing at 40 – 49 years. This finding
agrees with other studies on independent CVD risk fac-
tors, which showed an increase in prevalence with in-
crease in age [36, 37]. No significant predicted age
difference was observed in population with and without
IFG and IFG co-morbidity with risk factors, except in
overweight/obese. In other words, IFG or its co-morbid
risk condition do not have age preference unlike in dia-
betes where the age difference was found to be statisti-
cally significant (p < 0.018) between age of occurrence
(Table 4). However, the fact that co-existence of other
risk factors with impaired glucose regulation increases
the risk of chronic diabetes and CVD [38], underscores
the need for frequent risk assessment for prediabetes in
this population. Establishment of opportunistic screen-
ing strategies using already available communicable dis-
ease screening centres would be a cost-efficient
approach.
Our findings also showed that predicted age of IFG,
diabetes and their co-occurrence with other risk factors
were within same range (40 – 45 years). Evidence shows
that risk assessment models for CVD have diabetes as
dichotomous (Yes or No) and considers subjects from
40 years of age. It is argued that the problem of such di-
chotomy is that hyperglycaemia in impaired fasting glu-
cose or impaired glucose tolerance is missed via a NO
Table 3 Prevalence of IFG and diabetes co-morbidity with other CVD risk factors across age groups





















18-29 30 (5.3) 24 (4.2) 9 (1.6) 11 (1.9) 12 (2.1) 11 (1.9) 5 (0.9) 8 (1.4)
30-39 21 (4.2) 19 (3.8) 4 (0.8) 13 (2.6) 9 (1.8) 8 (1.6) 3 (0.6) 5 (1.0)
40-49 35 (6.9) 29 (5.8) 13 (2.6) 19 (3.8) 19 (3.8) 16 (3.2) 10 (2.0) 12 (2.4)
50-59 25 (5.8) 23 (5.3) 11 (2.6) 17 (4.0) 16 (3.7) 13 (3.0) 8 (1.9) 10 (2.3)
60-69 28 (8.0) 25 (7.2) 7 (2.0) 15 (4.3) 11 (3.2) 9 (2.6) 6 (1.7) 10 (2.9)
70-89 2 (2.1) 2 (2.1) 1 (1.1) 1 (1.1) 9 (9.6) 8 (8.5) 1 (1.1) 3 (3.2)
Total 141 (5.8) 122 (5.0) 45 (1.8) 76 (3.1) 76 (3.1) 65 (2.7) 33 (1.3) 48 (2.0)
Table 4 Age (years) of IFG and diabetes co-morbidity with CVD
risk factors
CVD risk factors Status Predicted
age (years)
N % satisfied ESS p-value
IFG Yes ≥40 1376 6.54 8.06 0.253
No <40 1071 4.76
IFG with
Dyslipidaemia
Yes ≥41 1274 5.97 10.77 0.091
No <41 1173 3.92
IFG with HBP Yes ≥41 1274 2.43 17.14 0.096
No <41 1173 1.19
IFG with
Overweight/Obese
Yes ≥41 1274 4.00 15.52 0.033
No <41 1173 2.13
Diabetes Yes ≥40 1376 4.00 16.65 0.018
No <40 1071 1.96
Diabetes with
Dyslipidaemia
Yes ≥44 1169 3.51 15.72 0.052
No <44 1278 1.88
Diabetes with HBP Yes ≥40 1376 1.82 19.79 0.010
No <40 1071 0.75
Diabetes with
Overweight/Obese
Yes ≥42 1255 2.63 17.81 0.063
No <42 1192 1.26
N number of observations in a given predicted class category, % satisfied
percentage of observations in a given class category, ESS effect strength for
sensitivity, HBP high blood pressure
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answer, when assessment and treatment of CVD risk in
prediabetes should be as in diabetes [39, 40]. The impli-
cation is that information pertaining to the primordial
forms of glucose dysregulation are not brought to fore in
Nigeria to aid early identification of the ‘at risk’ popula-
tion, since risk of an individual is usually not assessed
until overt diabetes that surfaces with huge symptoms.
This emphasises that intervention based on outcome of
utilisation of available risk assessment tools would not
identify a substantial proportion of the population at in-
creased risk of CVD, given the proportion of IFG indi-
viduals with co-morbid risk factors.
Furthermore, our findings delineated high level of
blood total cholesterol as the most important risk factor
predominant in population with IFG. Some studies in
Nigeria identified high prevalence of risk factors [41–
43], and insight into the order of importance and occur-
rence would assist in screening and treatment of the at-
risk individuals. However, based on chain of events as
shown in Figs. 1 and 2, it may seem important to inte-
grate screening for hypertriglyceridaemia in risk assess-
ment models for prediabetes conditions in the Nigerian
population, as it strongly contributes to the co-
morbidity in IFG-normocholesterolaemic-overweight/
obese-nonhypertensive individuals. This implies that in
the absence of HBP, there is increased chance of dyslipi-
daemia (high total cholesterol and/or triglyceride levels)
and overweight/obese among the sample population
with IFG. Furthermore, hypertriglyceridaemia was found
to have higher independent predictive ability in classify-
ing IFG than age. It was opined to be an essential risk
factor contributing to discordance of results from the
use of the ATPIII/Framingham risk score and metabolic
syndrome in screening individuals at 10-year risk of
CVD [44].
The increasing identification of IFG and undiagnosed
diabetes is an issue for concern, requiring concerted and
pragmatic approach. It is important to emphasise the
need for screening of IFG at least, based on the evidence
of high co-morbid CVD risk factors associated with it.
The feasibility of screening by measuring FBG levels
leads to increased chances of early identification when
targeted at patients with multiple risk factors [45]. The
epidemiological evidence that the majority of cases of
diabetes/CVD are undiagnosed in this part of the world
is an indication that assessment and management of
CVD risk based on screening for diabetes in subjects
with high blood pressure [46] may miss out early identi-
fication of other risk factors that co-exist in individuals
without evidence of hypertension. This is on the premise
that the etiological mechanisms of clustering of the
CVD risk factors are not well understood. However, one
of the factors undermining risk screening of dyslipidae-
mia in Nigeria is the high cost [20, 47], and although
obesity screening is affordable, there is no evidence re-
garding its assessment against mortality outcome other
than metabolic outcome, and in most cases the propor-
tion of metabolically healthy obese phenotype is not
accounted for in studies reporting high prevalence of
obesity. Therefore, future studies exploring association
of these phenotypes with prediabetes and other risk fac-
tors are required to elucidate the order of magnitude of
IFG/IGT co/multi-morbidity with CVD risk factors in
sub-Sahara Africa.
Strength and Limitations of the study
One of the strength of the study is that it comprises of
treatment naïve individuals for the assessed risk factors.
Also, to the best of our knowledge, this is the only pub-
lished study that has investigated the co-morbidity of
Fig. 1 Order of independent predictive performance of the risk factors in classifying IFG. TC = elevated total cholesterol, TG = hypertrglyceridemia,
HDL = High density lipoprotein cholesterol. Overweight/obese is based on body mass index, population = rural vs urban population
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IFG with other modifiable CVD risk factors and the
order of importance of the IFG co-morbid risk factors in
apparently healthy Nigerians. The use of a nonlinear
multivariate classification method that is not influenced
by assumptions of multicolinearity, multivariate normal-
ity, equality of group sizes, or number of variables is an
added strength. The point of care analysis was carried
out within manufacturers recommended operational
temperature range, and this was confirmed by device
logs used.
Diabetes mellitus is known to be heterogeneous, where
differences in glucose regulation exist among individuals
with comparable diagnostic glucose levels [48]. One of
the limitations of this study is use of FBG measurement
to classify diabetes. Although cost prohibitive it would
be worth using HbA1c, which is now available as a point
of care test as an additional screening tool.
Conclusion
The higher prevalence of co-morbidity of CVD risk fac-
tors with IFG than in diabetes mellitus shows that tar-
geting only the older adult individuals presenting at
health institutions for risk factors identification and
intervention would not abate the increasing incidence of
diabetes and CVD in Africa. There is need for appropri-
ate risk assessment models for prediabetes considering
that IFG and its co-morbid risk factors are relative
prevalent in young adults and probably more in middle-
aged adults.
Fig. 2 Hierarchically Optimal Classification Tree Analysis Model (via UniODA) of IFG subjects with risk factors. High TC = high level of total
cholesterol; high TG = high level of triglyceride; overweight/obese is based on body mass index; ESS = effect strength for sensitivity
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